CLYM News and Press, Climb Bio Inc.

2026-03-26 06:54:42 ET B. Riley Financial upgraded shares of Climb Bio ( NASDAQ:CLYM – Free Report ) to a strong-buy rating in a research report released on Monday, Zacks.com reports. Several other equities research analysts have also commented on CLYM. Wedbus...

2026-03-10 18:03:33 ET Christopher Raymond from Raymond James issued a price target of $25.00 for CLYM on 2026-03-10 20:06:00. The adjusted price target was set to $25.00. At the time of the announcement, CLYM was trading at $7.33. The overall price target consensus is a...

2026-03-05 16:55:50 ET More on Climb Bio Cheap high flyer healthcare stocks - high momentum and low valuation Seeking Alpha’s Quant Rating on Climb Bio Historical earnings data for Climb Bio Financial information for Climb Bio Read the full a...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with ...

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 a.m. ...

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed ...

WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed ...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

2025-08-12 11:51:25 ET More on Climb Bio Climb Bio appoints Edgar D. Charles as Chief Medical Officer Seeking Alpha’s Quant Rating on Climb Bio Historical earnings data for Climb Bio Financial information for Climb Bio Read the full article o...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks Budoprutug Subcutaneous Formulation Demonstrated High Bioavailability ...